Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 17/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715034 | 0.93 | HPRT1 (0.70) | HPRT1CYP3A4 | |
| SCHEMBL4713142 | 0.93 | HPRT1 (0.70) | HPRT1CYP3A4 | |
| SCHEMBL172846 | 0.93 | HPRT1 (0.70) | HPRT1CYP3A4 | |
| SCHEMBL97295 | 0.92 | HPRT1 (0.64) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| Pyrophosphoric Acid SCHEMBL15054252 | 0.89 | HPRT1 (0.66) | HPRT1CYP3A4POLB | |
| Pyrophosphoric Acid SCHEMBL15053837 | 0.89 | HPRT1 (0.66) | HPRT1CYP3A4POLB | |
| Pyrophosphoric Acid SCHEMBL15054286 | 0.89 | HPRT1 (0.66) | HPRT1CYP3A4POLB | |
| SCHEMBL15078152 | 0.87 | POLB (0.68) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL17197915 | 0.86 | HPRT1 (0.58) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL15054501 | 0.85 | HPRT1 (0.56) | HPRT1MEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | TERT, POT1, TERF2 | HPRT1 41/4885MEN1 936/4885ALDH1A1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.